Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections May 31, 2024
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem Apr 29, 2024
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 Mar 21, 2024
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections Jan 30, 2024
